Introduction and Objective: The 52-week QWINT-2 phase 3 trial demonstrated non-inferiority in HbA1c change from baseline with low, comparable hypoglycemia rates for efsitora, a novel once-weekly basal insulin (N=466), vs degludec (N=462) in insulin-naïve adults with type 2 diabetes (T2D). Here, we report the patient-reported outcomes.Methods: The TRIM-D assessed 5 domains: treatment burden, daily life, diabetes management, compliance, and psychological health, plus a total score indicating overall health. The SIM-Q evaluated treatment complexity, and the BIE assessed likelihood of a participant incorporating study insulin into their routine.Results: At week 52, there were significantly greater improvements in TRIM-D total score and in diabetes management and treatment burden domains with efsitora vs degludec (Figure). On the SIM-Q and BIE, more participants rated efsitora as “very simple” (51%) vs degludec (34%; P<0.001) and “very likely” to incorporate into their treatment routine (50%) vs degludec (38%; P=0.003), respectively.Conclusion: Weekly efsitora treatment resulted in a better overall health state, easier management, and reduced treatment burden vs daily degludec in insulin-naïve adults with T2D, with a greater simplicity perception by the participants. These findings may reduce insulin initiation inertia and delays in T2D management.
H.S. Bajaj: Research Support; Abbott, Amgen Inc, Anji Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, GlaxoSmithKline plc, Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc. C.H. Wysham: Advisory Panel; Abbott. Research Support; AbbVie Inc, Eli Lilly and Company. Speaker’s Bureau; MannKind Corporation. Research Support; Novo Nordisk. Speaker’s Bureau; Eli Lilly and Company. Research Support; Novo Nordisk, Bayer Pharmaceuticals, Inc. I. Lingvay: Consultant; Abbvie, Altimmune, Amgen, Alveus Tx, Antag Tx, Astra Zeneca, Bayer, Betagenon AB, Bioio Inc., Biomea, Boehringer-Ingelheim, Carmot, Cytoki Pharma, Eli Lilly, Intercept, Janssen/J&J, Juvena, Keros Ther, Novo Nordisk, Pharmaventures, Pfizer, Regeneron, Roche, Sanofi, Shionogi, Source Bio, Structure Therapeutics, TARGET RWE, TERNS Pharma, The Comm Group, WebMD, and Zealand Pharma. Research Support; Novo Nordisk, Sanofi, Boehringer-Ingelheim. T. Vilsbøll: Advisory Panel; Boehringer-Ingelheim, AstraZeneca, Bristol-Myers Squibb Company, Carmot Therapeutics, Inc. Research Support; Dexcom, Inc. Advisory Panel; Eli Lilly and Company, GlaxoSmithKline plc. Speaker’s Bureau; Medscape. Advisory Panel; Novo Nordisk, Sun Pharmaceutical Industries Ltd, Roche Diabetes Care, Amgen Inc, Sanofi, Zealand Pharma A/S. L. Firmino Goncalves: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. C. Zhou: Employee; Eli Lilly and Company. M.B. Davidson: Employee; Eli Lilly and Company. A. Knights: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. F. Gelsey: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.
Source link
Leave a Reply